News
Following a meeting with the US FDA, clinical-stage biotech Dimerix has confirmed the appropriate primary endpoint for full ...
The Manila Times on MSN19h
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclei…Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at ...
Clinical Trials Arena on MSN17h
FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGSThe US Food and Drug Administration (FDA) has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback